Latest Earnings Results: Q3 '26
Estimated EPS
$0.03
Reported EPS
$0.05
Surprise
+77.69%
Estimated Rev
$255.37M
Reported Rev
$275.36M
Surprise
+7.83%
• Reported GAAP EPS of $0.05 down -37.50% YoY • Reported revenue of $275.36M up 26.99% YoY • Caris Life Sciences now expects full year 2026 revenue of $1.04B, representing growth of 28% to 29% versus 2025, and reaffirms clinical therapy selection volume growth of approximately 20%.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $0.07 | -- | -- | N/A |
Q3 '26 | $0.03 | $0.05 | 77.69% | BEAT |
Q2 '26 | $0.01 | $0.00 | -100.00% | MISSED |
Q1 '26 | -$0.02 | $0.00 | 100.00% | BEAT |
Q4 '25 | $0.03 | $0.28 | 723.07% | BEAT |